Bladder cancer from bench to bedside: Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Has parts
Paper 1: Søgaard, Caroline Krogh; Blindheim, Augun; Røst, Lisa Marie; Petrovic, Voin; Nepal, Anala; Bachke, Siri; Liabakk, Nina-Beate; Gederaas, Odrun Arna; Viset, Trond; Arum, Carl-Jørgen; Bruheim, Per; Otterlei, Marit. "Two hits - one stone" increased efficacy of cisplatin-based therapies by targeting PCNA's role in both DNA repair and cellular signaling. OncoTarget 2018 ;Volum 9.(65) s. 32448-32465 https://doi.org/10.18632/oncotarget.25963 This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0)Paper 2: Blindheim, Augun Jodis; Fosså, Sophie Dorothea; Babigumira, Ronnie; Myklebust, Tor Åge; Haug, Erik Skaaheim; Arum, Carl-Jørgen; Kulle, Bettina. T1 bladder cancer in Norway: treatment and survival. Scandinavian Journal of Urology 2020 ;Volum 54.(5) s. 370-375 https://doi.org/10.1080/21681805.2020.1803401 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Paper 3: Blindheim, A.; Fosså, S.; Babigumira, R.; Andreassen, B K The use of reTURB in T1 bladder cancer, a Norwegian population-based study. - the final published version is available in Scandinavian Journal of Urology https://doi.org/10.1080/21681805.2021.1917652 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/)